Postdoctoral and clinical fellows are invited to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grant by June 21, 2023.
This three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry, while allowing recipients to spend one year at a Johnson & Johnson facility.
Applicants must be female or belong to one of the underrepresented groups as per the NIH guidelines (Notice of NIH’s Interest in Diversity), and the research proposal must have direct applicability to lung cancer.
The AACR-Lung Cancer Initiative at Johnson & Johnson START Grant represents an opportunity to address the need for promoting and supporting academia-industry collaborations.
It is hoped that the training provided through this initiative will be invaluable to young investigators by providing fellows with a comprehensive research experience that will make them desirable to potential employers in either academic research or the pharmaceutical industry.
Research proposals focused on mechanisms linking immunogenic cell death pathways to amplification of innate and adaptive immunity, immunobiology of non-small cell lung cancers, and mechanisms of acquired resistance to immunotherapies are highly encouraged.
